Paris, July 29 (Bernama-GLOBE NEWSWIRE) —
Second-quarter 2019 sales growth(3) driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets
- Net sales were €8,628 million, up 5.5% on a reported basis, up 3.9%(3) at CER and up 5.8% at CER/CS(4).
- Sanofi Genzyme sales up 21.8% due to strong launch performance of Dupixent®.
- Vaccines sales increased 24.7% mainly reflecting the recovery and growth of Pentaxim® in China and low basis for comparison.
- CHC sales up 1.1%, as U.S. growth more than offset lower sales in Europe impacted by non-strategic brand divestments.
- Primary Care GBU sales declined 10.4% at CER/CS mainly as a result of lower Diabetes sales.
- Emerging Markets sales(5) grew double-digits (up 10.0%) supported by higher Vaccines and Rare Disease sales.